Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Por um escritor misterioso
Descrição
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. - Abstract - Europe PMC
Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy - Pires da Silva - 2020 - Cancer - Wiley Online Library
Melanoma brain metastases, immunotherapy as standard of care
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology
Ipilimumab (Yervoy) Drug Information
Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma - The ASCO Post
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology
1694-Melanoma metastatic ipilimumab and nivolumab (induction)
Cancers, Free Full-Text
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920 - Emamekhoo - 2022 - Cancer - Wiley Online Library
ABC-X Clinical Trial - Melanoma Institute Australia
PDF) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
